Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Potential chemo-free therapy in triple-positive mBC with ribociclib

Wolfgang Janni • 14 Sep 2024
ESMO 2024
Breast Cancer Ribociclib
DETECT V

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses the potential for chemo-free therapy in triple-positive metastatic breast cancer (mBC) by incorporating ribociclib. Ongoing results from the Phase III DETECT V trial (NCT02344472) and other randomized studies are eagerly awaited to determine the viability of this approach. If successful, ribociclib could become a standard first-line treatment for patients with triple-positive mBC, offering a less intensive alternative to traditional chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wolfgang Janni

Using ctDNA in breast cancer clinical trials
2:09
Using ctDNA in breast cancer clinical trials
Wolfgang Janni • 13 Mar 2025
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
2:19
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
Wolfgang Janni • 13 Mar 2025
The emerging role of ctDNA in screening & monitoring early breast cancer
0:41
The emerging role of ctDNA in screening & monitoring early breast cancer
Wolfgang Janni • 13 Mar 2025
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
1:44
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
Wolfgang Janni • 13 Mar 2025

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals